Lung cancer in never smokers: Tumor immunology and challenges for immunotherapy

Author(s)

de Alencar, Viviane Teixeira L. ; Figueiredo, Amanda B. ; Corassa, Marcelo ; Gollob, Kenneth J. ; de Lima, Vladmir Cordeiro C.

• Document type: Journal article
• Source: FRONTIERS IN IMMUNOLOGY; v. 13, p. 14-pg., 2022-08-24.

Abstract

Lung cancer is the second most common and the most lethal malignancy worldwide. It is estimated that lung cancer in never smokers (LCINS) accounts for 10-25% of cases, and its incidence is increasing according to recent data, although the reasons remain unclear. If considered alone, LCINS is the 7th most common cause of cancer death. These tumors occur more commonly in younger patients and females. LCINS tend to have a better prognosis, possibly due to a higher chance of bearing an actionable driver mutation, making them amenable to targeted therapy. Notwithstanding, these tumors respond poorly to immune checkpoint inhibitors (ICI). There are several putative explanations for the poor response to immunotherapy: low immunogenicity due to low tumor mutation burden and hence low MANA (mutation-associated neo-antigen) load, constitutive PD-L1 expression in response to driver mutated protein signaling, high expression of immunosuppressive factors by tumors cells (like CD39 and TGF-beta), non-permissive immune TME (tumor microenvironment), abnormal metabolism of amino acids and glucose, and impaired TLS (Tertiary Lymphoid Structures) organization. Finally, there is an increasing concern of offering ICI as first line therapy to these patients owing to several reports of severe toxicity when TKIs (tyrosine kinase inhibitors) are administered sequentially after ICI. Understanding the biology behind the immune response against these tumors is crucial to the development of better therapeutic strategies. (AU)

• FAPESP's process: 21/00408-6 - Center for Research in Immuno-Oncology (CRIO)
• Grantee: Kenneth John Gollob
• Support Opportunities: Research Grants - Research Centers in Engineering Program